Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort
Puey Ling Chia, Prudence Russell, Khashi Asadi, Bibhusal Thapa, Val Gebski, Carmel Murone, Marzena Walkiewicz, Ulf Eriksson, Andrew M Scott, Thomas John
Lung Cancer | ELSEVIER IRELAND LTD | Published : 2020
BACKGROUND: Malignant mesothelioma (MM) is an aggressive malignancy of the pleura and other mesothelial membranes. Agents targeting vascular endothelial growth factor (VEGF) such as bevacizumab; and multi-kinase inhibitors such as nintedanib [angiokinase inhibitor of VEGF, platelet-derived growth factor (PDGF) receptor and fibroblast growth factor receptor (FGFR)] have recently demonstrated efficacy in MM. METHODS: Tissue microarrays (TMAs) were created from formalin-fixed, paraffin-embedded tissue samples obtained from 326 patients with MM who were treated surgically. PDGF-CC, FGFR-1, VEGF and CD31 expression were analysed by immunohistochemical (IHC) staining. The H-score method assigned a..View full abstract
This study is supported by a mesothelioma project grant from Cancer Council Victoria in partnership with Victorian Cancer Agency. Puey Ling Chia was supported by International Association for the Study of Lung Cancer (IASLC) Fellowship Award and The University of Melbourne, Australian Postgraduate Award. Thomas John was a recipient of a NHMRC Early Career Fellowship and Andrew Scott a NHMRC Practitioner Fellowship. The Olivia Newton-John Cancer Research Institute acknowledges the support of the Victorian Government Operational and Infrastructure Support Program.